Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.

Chi XuYahui WangYuanyuan HongRu YaoLijia WuXi ShenYang QuZhuo ZhangWei ZhuYing YangWeizhi ChenYidong ZhouZhiyong Liang

Published in: Breast cancer research and treatment (2023)

Aberrant activation of multiple pathways and low baseline tumor-infiltrating B cells are related to HER2 + BC trastuzumab-based recurrence, which primarily affects the antitumor activity of trastuzumab.

Keyphrases

positive breast cancer
epidermal growth factor receptor
metastatic breast cancer
genome wide
free survival
tyrosine kinase
dna methylation
combination therapy
gene expression